Virgin Galactic Holdings, Inc. vs Zoetis Inc — how do they compare? Virgin Galactic Holdings, Inc. trades at $2.99 (market cap $474.50M), while Zoetis Inc trades at $73.95 (market cap $30.40B). The key difference: Zoetis Inc is far larger — about 64.1× Virgin Galactic Holdings, Inc.'s market cap, and Zoetis Inc pays a 2.88% dividend while Virgin Galactic Holdings, Inc. pays none. Which is the better fit depends on your goals.
| SPCE | ZTS | |
|---|---|---|
Market Cap | $474.50M | $30.40B |
Sector | Industrials | Health |
52-Week High | $7.52 | $150.61 |
52-Week Low | $2.17 | $71.91 |
Enterprise Value | $438.48M | $37.96B |
Dividend Yield | — | 2.88% |
Signals from Pluang's Aura AI — not financial advice
Virgin Galactic (SPCE) trades at $3.13, up 2.96% with a bullish technical outlook from moving averages. The company continues to report significant losses with negative profit margins and cash flow, though recent quarters have shown earnings beats. Management targets positive cash flow by 2027, but commercial spaceflight delays to February 2027 create execution risk. Analyst sentiment is divided with 29% buy, 41% hold, and 29% sell ratings.
SPCE represents a high-risk, speculative opportunity in the emerging space tourism sector. The path to profitability remains distant with substantial cash burn, though strong ticket demand provides potential upside if execution improves. Key risks include ongoing dilution, high short interest, and the capital-intensive nature of space operations. Investors should weigh the long-term potential against persistent financial challenges.
Zoetis (ZTS) trades at $73.60, down 2.92% amid bearish technical signals and mixed earnings. The stock faces pressure from weakening U.S. companion animal sales and competitive headwinds, though profitability remains strong with 71.67% gross margins and 27.69% net income margin. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a guidance cut. Analyst consensus is divided with 45% Buy ratings and a $93.40 price target, suggesting 27% upside from current levels.
The outlook balances valuation appeal (P/E of 12) against near-term operational challenges. Investment opportunity lies in market dominance and robust cash flow generation, while risks include sustained pet health demand softness and competitive pricing pressure. The stock trades near support at $73, with institutional sentiment mixed amid recent portfolio adjustments.
Trailing returns across standard periods
Latest headlines on both assets
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →